Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alissa Hudson

Ophthalmology Cookeville, TN Medical Doctor

NPI 1558393173 CMS profile 296946

600 E Veterans Dr, Suite A, Cookeville, TN 38501

Open in the dashboard

General payments

$4,778

273 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alissa Hudson of Cookeville, TN is reported in the CMS Open Payments database as having received $4,778 across 273 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,051 55
2024 General $1,046 59
2023 General $787 50
2022 General $545 32
2021 General $561 39
2020 General $450 19
2019 General $337 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alissa Hudson
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Alissa Hudson were reported at $1,051. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Alissa Hudson Ophthalmology median Middle half National median
2019 $337 $258 $104–$655 $163
2020 $450 $126 $45–$321 $114
2021 $561 $205 $76–$534 $132
2022 $545 $266 $100–$678 $149
2023 $787 $308 $117–$745 $160
2024 $1,046 $340 $127–$846 $164
2025 $1,051 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alcon Vision LLC $1,330 79 payments
  2. AbbVie, Inc. $898 54 payments
  3. Allergan Inc. $500 32 payments
  4. Johnson & Johnson Surgical Vision, Inc. $300 10 payments
  5. Horizon Therapeutics plc $300 22 payments
  6. Harrow Eye, LLC $208 10 payments
  7. Amgen Inc. $192 17 payments
  8. Sight Sciences, Inc. $114 7 payments
  9. Tarsus Pharmaceuticals, Inc. $94 4 payments
  10. Glaukos Corporation $94 4 payments
  11. Other $747 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,668 270 payments
  2. Education $91 2 payments
  3. Gift $19 1 payment
Products named General payments · program years 2019–2025
  1. DURYSTA Glaucoma $592 35 payments
  2. DURYSTA Eye Care $421 30 payments
  3. TEPEZZA Tepezza $300 22 payments
  4. Tecnis Simplicity $274 8 payments
  5. LUMIGAN $237 11 payments
  6. ARGOS $234 19 payments
  7. Clareon $225 14 payments
  8. TEPEZZA Inflammation/Rare Disease $192 17 payments
  9. VEVYE $173 8 payments
  10. Clareon PanOptix Pro $162 4 payments
  11. Other $2,530 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

2,128

Median for Ophthalmology: 891

Drug cost

$1,608,954

Median for Ophthalmology: $68,233

Branded share of claims

56.3%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tepezza Teprotumumab-Trbw Brand 26 $1,371,594
Restasis Cyclosporine Brand 71 $68,109
Lumigan Bimatoprost Brand 69 $41,669
Combigan Brimonidine Tartrate/Timolol Brand 46 $22,887
Xiidra Lifitegrast Brand 20 $16,773
Vevye Cyclosporine Brand 17 $14,976
Travoprost Generic 61 $14,669
Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol Brand 55 $10,114
Brimonidine Tartrate Generic 102 $9,396
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 294 $8,699

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$684,017

Of which drugs: $83,188

Medicare patients

1,888

Average age 75

Services billed

12,108

1,159 women, 729 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 34%
Ischemic heart disease 27%
Chronic kidney disease 22%
Depression 20%
Heart failure 17%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, bimatoprost, intracameral implant, 1 microgram J7351 Office 21 400 $64,962
Injection, onabotulinumtoxina, 1 unit J0585 Office 14 3,692 $18,220

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEPEZZA
$167 26 —
DURYSTA
$146 — 400
LUMIGAN
$117 69 —
XDEMVY
$53 — —
VEVYE
$47 17 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

273 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record